PTGX – Protagonist Therapeutics Inc
Float Short %
11.66
Margin Of Safety %
-23
Put/Call OI Ratio
0.1
EPS Next Q Diff
-0.06
EPS Last/This Y
-6.45
EPS This/Next Y
0.95
Price
58.83
Target Price
69.38
Analyst Recom
1.15
Performance Q
4.51
Relative Volume
0.78
Beta
2.19
Ticker: PTGX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-08-15 | PTGX | 56.09 | 0.24 | 0.05 | 3621 |
| 2025-08-18 | PTGX | 56.17 | 0.14 | 0.01 | 2981 |
| 2025-08-19 | PTGX | 56.25 | 0.14 | 0.20 | 2999 |
| 2025-08-20 | PTGX | 56.21 | 0.14 | 0.00 | 3001 |
| 2025-08-21 | PTGX | 55.99 | 0.14 | 0.00 | 3002 |
| 2025-08-22 | PTGX | 57.48 | 0.14 | 0.00 | 3004 |
| 2025-08-25 | PTGX | 56.91 | 0.14 | 0.03 | 3011 |
| 2025-08-26 | PTGX | 57.23 | 0.14 | 0.00 | 3065 |
| 2025-08-27 | PTGX | 61.44 | 0.14 | 0.08 | 3066 |
| 2025-08-28 | PTGX | 58.12 | 0.11 | 0.00 | 3108 |
| 2025-08-29 | PTGX | 59 | 0.11 | 0.01 | 3387 |
| 2025-09-02 | PTGX | 58.82 | 0.09 | 0.00 | 3947 |
| 2025-09-03 | PTGX | 58.1 | 0.09 | 0.00 | 3972 |
| 2025-09-04 | PTGX | 59.4 | 0.09 | 0.00 | 3953 |
| 2025-09-05 | PTGX | 60.55 | 0.10 | 0.00 | 3599 |
| 2025-09-08 | PTGX | 56.24 | 0.11 | 1.65 | 3278 |
| 2025-09-09 | PTGX | 58.4 | 0.13 | 0.01 | 3362 |
| 2025-09-10 | PTGX | 57.72 | 0.10 | 0.00 | 4227 |
| 2025-09-11 | PTGX | 59.65 | 0.10 | 0.28 | 4287 |
| 2025-09-12 | PTGX | 58.85 | 0.10 | 0.00 | 4318 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-08-15 | PTGX | 56.08 | -14.1 | - | -1.98 |
| 2025-08-18 | PTGX | 56.19 | -14.1 | - | -1.98 |
| 2025-08-19 | PTGX | 56.25 | -14.1 | - | -1.98 |
| 2025-08-20 | PTGX | 56.24 | -14.1 | - | -1.98 |
| 2025-08-21 | PTGX | 56.04 | -14.1 | - | -1.98 |
| 2025-08-22 | PTGX | 57.53 | -14.1 | - | -1.98 |
| 2025-08-25 | PTGX | 56.91 | -14.1 | - | -1.98 |
| 2025-08-26 | PTGX | 56.99 | -14.1 | - | -1.98 |
| 2025-08-28 | PTGX | 58.14 | -14.1 | - | -1.98 |
| 2025-08-29 | PTGX | 59.05 | -14.1 | - | -1.98 |
| 2025-09-02 | PTGX | 58.83 | -14.1 | - | -1.98 |
| 2025-09-03 | PTGX | 58.12 | -14.1 | - | -1.98 |
| 2025-09-04 | PTGX | 59.62 | -14.1 | - | -1.98 |
| 2025-09-05 | PTGX | 60.53 | -14.1 | - | -1.98 |
| 2025-09-08 | PTGX | 56.19 | -14.1 | - | -1.98 |
| 2025-09-09 | PTGX | 58.39 | -14.1 | - | -1.98 |
| 2025-09-10 | PTGX | 57.73 | -14.1 | - | -1.98 |
| 2025-09-11 | PTGX | 59.68 | -14.1 | - | -1.98 |
| 2025-09-12 | PTGX | 58.83 | -14.1 | - | -1.98 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-08-15 | PTGX | -3.98 | -0.37 | 9.82 |
| 2025-08-18 | PTGX | -3.98 | 0.23 | 9.80 |
| 2025-08-19 | PTGX | -4.12 | 0.23 | 9.80 |
| 2025-08-20 | PTGX | -4.12 | 0.23 | 9.80 |
| 2025-08-21 | PTGX | -3.98 | 0.23 | 9.80 |
| 2025-08-22 | PTGX | -3.98 | 0.23 | 9.80 |
| 2025-08-25 | PTGX | -3.98 | 14.81 | 9.80 |
| 2025-08-26 | PTGX | -3.98 | 14.81 | 9.80 |
| 2025-08-27 | PTGX | -3.98 | 14.81 | 10.75 |
| 2025-08-28 | PTGX | -3.98 | 14.81 | 10.75 |
| 2025-08-29 | PTGX | -3.98 | 14.81 | 10.75 |
| 2025-09-02 | PTGX | -4.08 | 15.10 | 10.74 |
| 2025-09-03 | PTGX | -4.13 | 15.10 | 10.74 |
| 2025-09-04 | PTGX | -4.14 | 15.10 | 10.74 |
| 2025-09-05 | PTGX | -4.14 | 15.10 | 10.74 |
| 2025-09-08 | PTGX | -4.14 | 15.15 | 10.74 |
| 2025-09-09 | PTGX | -4.14 | 15.15 | 10.74 |
| 2025-09-10 | PTGX | -4.14 | 15.15 | 10.74 |
| 2025-09-11 | PTGX | -4.08 | 15.15 | 11.66 |
| 2025-09-12 | PTGX | -4.08 | 15.15 | 11.66 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.55
Avg. EPS Est. Current Quarter
-0.62
Avg. EPS Est. Next Quarter
-0.61
Insider Transactions
-4.08
Institutional Transactions
15.15
Beta
2.19
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
32
Fair Value
45.47
Quality Score
56
Growth Score
58
Sentiment Score
23
Actual DrawDown %
4.9
Max Drawdown 5-Year %
-85.8
Target Price
69.38
P/E
82.6
Forward P/E
358.49
PEG
P/S
17.51
P/B
5.47
P/Free Cash Flow
98.7
EPS
0.71
Average EPS Est. Cur. Y
-1.98
EPS Next Y. (Est.)
-1.03
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
24.88
Relative Volume
0.78
Return on Equity vs Sector %
-17.1
Return on Equity vs Industry %
-3.9
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.33
EBIT Estimation
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 130
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading